Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the benzophenone class. It is known as a balanol analog and has been studied primarily as an experimental inhibitor of protein kinases. Specifically, it acts as an ATP-site competitive inhibitor of cAMP-dependent protein kinase (protein kinase A), and may also inhibit other related kinases such as serum/glucocorticoid regulated kinase family member SGK3. Its structure is based on modifications of balanol, a natural product known for potent inhibition of serine/threonine kinases[1][6][7][10]. The compound has not been approved for clinical use and remains experimental.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-[(3-sec-butyl-4-hydroxybenzoyl)amino]azepan-4-yl 4-(2-hydroxy-5-methoxybenzoyl)benzoate.